Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member

Paris (France), November 23, 2021 – 7 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the appointment of Bryan Giraudo as independent member of the Board of Directors, replacing Thomas Hofstaetter after three mandates.

Bryan Giraudo is both the Chief Operating Officer & Chief Financial Officer of Gossamer Bio, a U.S. listed biopharmaceutical company (Nasdaq: GOSS) focused on developing and commercializing innovative therapeutics in the areas of immunology, inflammation and oncology. Previously, he served as Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Mr Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Division.

Bryan Giraudo, new independent member of the Board of Directors of Onxeo, declared: “I am thrilled to join Onxeo’s Board of Directors, comprising outstanding experts in different clinical and strategic fields. I have been impressed by the Company’s technology targeting the tumor DNA Damage response and by the professionalism of the teams and I am happy to have the opportunity to support the development of the Company with my experience as an investment banker in the US life sciences sector as well as executive manager in a US Biotech.”

Shefali Agarwal, Chairwoman of the Board of Directors of Onxeo, commented: “On behalf of the entire Board of Directors I would like to thank Thomas Hofstaetter for his important contribution to the development of ONXEO during the past nine years. I am pleased to welcome Bryan Giraudo, whose arrival further strengthens our international focus and brings to the Company a strong financial experience and a broad network within the investment community in the US.”

Judith Greciet, Chief Executive Officer of Onxeo, concluded: “With Bryan joining our Board of Directors today, I am glad that our Company was able to attract such an outstanding group of seasoned professionals. This clearly shows the growing interest and awareness of our unique approach in the field of DNA Damage Response internationally. The very complementary strategic advice from our Board members will be instrumental for our ambitious development program with AsiDNA™, notably in the United States.”